275 ORAL First-line bevacizumab and paclitaxel in patients with locally recurrent or metastatic breast cancer: a randomized, phase III trial coordinated by the Eastern Cooperative Oncology Group (E2100)

Eastern Cooperative Oncology Group ◽

Metastatic Breast ◽

Phase Iii ◽

Oncology Group ◽

First Line ◽

Phase Iii Trial ◽

OT2-01-02: First-Line Bevacizumab in Combination with Capecitabine or Paclitaxel for HER2−Negative Locally Recurrent or Metastatic Breast Cancer (LR/MBC): A Randomized Phase III Trial.

10.1158/0008-5472.sabcs11-ot2-01-02 ◽

2011 ◽

Author(s):

S Beslija ◽

T Brodowicz ◽

R Greil ◽

MJ Inbar ◽

Z Kahán ◽

...

Keyword(s):

Breast Cancer ◽

Metastatic Breast ◽

Phase Iii ◽

First Line ◽

Phase Iii Trial ◽

Hormonal treatment for metastatic breast cancer. An eastern cooperative oncology group phase III trial comparing aminoglutethimide to tamoxifen

Cancer ◽

10.1002/1097-0142(19940115)73:2<354::aid-cncr2820730220>3.0.co;2-j ◽

1994 ◽

Vol 73 (2) ◽

pp. 354-361 ◽

Cited By ~ 43

Author(s):

Kenneth E. Gale ◽

Janet W. Andersen ◽

Douglass C. Tormey ◽

Edward G. Mansour ◽

Thomas E. Davis ◽

...

Keyword(s):

Breast Cancer ◽

Eastern Cooperative Oncology Group ◽

Metastatic Breast ◽

Hormonal Treatment ◽

Phase Iii ◽

Oncology Group ◽

Phase Iii Trial

Faculty Opinions recommendation of AVEREL: a randomized phase III Trial evaluating bevacizumab in combination with docetaxel and trastuzumab as first-line therapy for HER2-positive locally recurrent/metastatic breast cancer.

Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature ◽

10.3410/f.717998592.793477025 ◽

2013 ◽

Author(s):

Ana Maria Gonzalez-Angulo

Keyword(s):

Breast Cancer ◽

Metastatic Breast ◽

Phase Iii ◽

First Line ◽

Her2 Positive ◽

Phase Iii Trial ◽

First Line Therapy ◽

Line Therapy ◽

Final results of the TANIA randomised phase III trial of bevacizumab after progression on first-line bevacizumab therapy for HER2-negative locally recurrent/metastatic breast cancer

Annals of Oncology ◽

10.1093/annonc/mdw316 ◽

2016 ◽

Vol 27 (11) ◽

pp. 2046-2052 ◽

Cited By ~ 18

Author(s):

E. Vrdoljak ◽

N. Marschner ◽

C. Zielinski ◽

J. Gligorov ◽

J. Cortes ◽

...

Keyword(s):

Breast Cancer ◽

Metastatic Breast ◽

Phase Iii ◽

First Line ◽

Phase Iii Trial ◽

Clinical Benefit Rate and Time to Response in RIBBON-1, a Randomized, Double-Blind, Phase III Trial of Chemotherapy with or without Bevacizumab (B) for the First-Line Treatment of HER2-Negative Locally Recurrent or Metastatic Breast Cancer (MBC).

10.1158/0008-5472.sabcs-09-6084 ◽

2009 ◽

Cited By ~ 4

Author(s):

N. Robert ◽

V. Dieras ◽

J. Glaspy ◽

A. Brufsky ◽

I. Bondarenko ◽

...

Keyword(s):

Breast Cancer ◽

Metastatic Breast ◽

Phase Iii ◽

Line Treatment ◽

First Line ◽

Double Blind ◽

Phase Iii Trial ◽

Locally Recurrent ◽

First Line Treatment

Gemcitabine, Epirubicin, and Paclitaxel Versus Fluorouracil, Epirubicin, and Cyclophosphamide as First-Line Chemotherapy in Metastatic Breast Cancer: A Central European Cooperative Oncology Group International, Multicenter, Prospective, Randomized Phase III Trial

Breast Diseases A Year Book Quarterly ◽

10.1016/s1043-321x(05)80313-3 ◽

2006 ◽

Vol 16 (4) ◽

pp. 378

Author(s):

A.D. Seidman

Keyword(s):

Breast Cancer ◽

Metastatic Breast ◽

Phase Iii ◽

Oncology Group ◽

First Line ◽

Phase Iii Trial ◽

Central European ◽

International Multicenter ◽

Line Chemotherapy

A randomized phase III trial of paclitaxel with or without bevacizumab as first-line therapy for locally recurrent or metastatic breast cancer: Eastern cooperative oncology group trial E2100

European Journal of Cancer Supplements ◽

10.1016/s1359-6349(06)80030-3 ◽

2006 ◽

Vol 4 (2) ◽

pp. 47 ◽

Cited By ~ 5

Author(s):

R. Zon ◽

Miller ◽

M. Wang ◽

J. Gralow ◽

M. Dickler ◽

...

Keyword(s):

Eastern Cooperative Oncology Group ◽

Metastatic Breast ◽

Phase Iii ◽

Oncology Group ◽

First Line ◽

Phase Iii Trial ◽

First Line Therapy ◽

Line Therapy ◽

Locally Recurrent ◽

Group Trial

Abstract CT322: Efficacy of first-line capecitabine (CAP) ± bevacizumab (BEV) according to risk factors in the RIBBON-1 randomized phase III trial in locally recurrent/metastatic breast cancer (LR/mBC)

10.1158/1538-7445.am2014-ct322 ◽

2014 ◽

Author(s):

Nicholas J. Robert ◽

Veronique Dieras ◽

Christian Jackisch ◽

Stefanie Srock ◽

Ulrich Freudensprung ◽

...

Keyword(s):

Breast Cancer ◽

Risk Factors ◽

Metastatic Breast ◽

Phase Iii ◽

First Line ◽

Phase Iii Trial ◽

Is epirubicin effective in first-line chemotherapy of metastatic breast cancer (MBC) after an epirubicin-containing adjuvant treatment? A single centre phase III trial

British Journal of Cancer ◽

10.1038/sj.bjc.6603096 ◽

2006 ◽

Vol 94 (9) ◽

pp. 1233-1236 ◽

Cited By ~ 21

Author(s):

C Pacilio ◽

◽

A Morabito ◽

F Nuzzo ◽

A Gravina ◽

...

Keyword(s):

Breast Cancer ◽

Adjuvant Treatment ◽

Metastatic Breast ◽

Phase Iii ◽

First Line ◽

Single Centre ◽

Phase Iii Trial ◽

Line Chemotherapy

A phase III trial of exemestane plus bevacizumab maintenance therapy in patients with metastatic breast cancer after first-line taxane and bevacizumab: a GINECO group study

Annals of Oncology ◽

10.1093/annonc/mdw077 ◽

2016 ◽

Vol 27 (6) ◽

pp. 1020-1029 ◽

Cited By ~ 14

Author(s):

O. Trédan ◽

P. Follana ◽

I. Moullet ◽

C. Cropet ◽

S. Trager-Maury ◽

...

Keyword(s):

Breast Cancer ◽

Maintenance Therapy ◽

Metastatic Breast ◽

Phase Iii ◽

First Line ◽

Phase Iii Trial